_id
69130b6bccc777a4e85d7c8a
Ticker
KRBPQ
Name
Kiromic BioPharma, Inc.
Exchange
PINK
Address
7707 Fannin Street, Houston, TX, United States, 77054
Country
USA
Sector
Healthcare
Industry
Biotechnology
Currency
USD
Website
https://www.kiromic.com
Description
Kiromic BioPharma, Inc., a clinical stage biotherapeutics company, engages in the utilization of non-engineered an engineered allogeneic Gamma Delta T (GDT) cell technologies to develop therapies for solid tumors in the United States. The company's lead product candidate is the Deltacel-01, which is in Phase 1 clinical trial, in combination with low-dose targeted radiation for patients with non-small cell lung cancer. It also develops Isocel, which is clinical trial in combination with low-dose radiation to treat Mesothelin Isoform 2 positive solid malignancies; Procel, which is in clinical trial in combination with low-dose radiation to treat PD-L1 positive solid malignancies; ALEXIS-ISO-1, which is in clinical trial to evaluate Isocel in patients with Mesothelin Isoform 2 positive solid malignancies; and ALEXIS-PRO-1, which is in clinical trial to evaluate Procel in patients with PD-L1 positive solid malignancies. It has a license agreement with Longwood University. The company was formerly known as Kiromic, Inc. and changed its name to Kiromic BioPharma, Inc. in December 2019. Kiromic BioPharma, Inc. was founded in 2006 and is headquartered in Houston, Texas. On March 21, 2025, Kiromic BioPharma, Inc. filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the District of Delaware.
Last Close
0.0001
Volume
-
Current Price
0.0001
Change
0
Last Updated
2026-01-04T16:10:28.143Z
Image
-
Ipo Date
-
Market Cap
-
Next Dividend Date
-
Dividend Frequency
-
Dividend Rate
-
Dividend Yield
0
Sentiment
-
Sentiment Sources
0
Current Quarter
2024-12-31
Revenue
0
Cost Of Revenue
-
Gross Profit
-
Operating Expenses
5705000
Operating Income
-5705000
Interest Expense
766000
Pretax Income
-6491000
Net Income
-6491000
Eps
-4.233430206773488
Dividends Per Share
-
Shares Outstanding
0
Income Tax Expense
-
EBITDA
-
Operating Margin
-
Total Other Income Expense Net
-20000
Cash
1137000
Short Term Investments
-
Receivables
-
Inventories
-
Total Current Assets
3301000
Property Plant Equipment
5223000
Total Assets
8545000
Payables
2676000
Short Term Debt
-
Long Term Debt
-
Total Liabilities
21132000
Equity
-12587000
Bs_currency_symbol
USD
Depreciation
568000
Change In Working Capital
-1859000
Cash From Operations
-3648000
Capital Expenditures
28000
Cash From Investing
-
Cash From Financing
2415000
Net Change In Cash
-1261000
Cf_currency_symbol
USD
PE
-
PB
-0.00001218139350123143
ROE
51.56907920870739
ROA
-75.96255119953189
FCF
-3676000
Fcf Percent
-
Piotroski FScore
1
Health Score
39
Deep Value Investing Score
0
Defensive Investing Score
6
Dividend Investing Score
1.5
Economic Moat Investing Score
5.3
Garp Investing Score
2
Growth Investing Score
2
Momentum Investing Score
2
Net Net Investing Score
0
Quality Investing Score
2.5
Value Investing Score
3
Quarters > 0 > quarter
2024-12-31
Quarters > 0 > income Statement > revenue
0
Quarters > 0 > income Statement > cost Of Revenue
-
Quarters > 0 > income Statement > gross Profit
-
Quarters > 0 > income Statement > operating Expenses
5705000
Quarters > 0 > income Statement > operating Income
-5705000
Quarters > 0 > income Statement > interest Expense
766000
Quarters > 0 > income Statement > pretax Income
-6491000
Quarters > 0 > income Statement > net Income
-6491000
Quarters > 0 > income Statement > eps
-4.233430206773488
Quarters > 0 > income Statement > dividends Per Share
-
Quarters > 0 > income Statement > shares Outstanding
1533272
Quarters > 0 > income Statement > income Tax Expense
-
Quarters > 0 > income Statement > EBITDA
-
Quarters > 0 > income Statement > operating Margin
-
Quarters > 0 > income Statement > total Other Income Expense Net
-20000
Quarters > 0 > income Statement > currency_symbol
USD
Quarters > 0 > balance Sheet > cash
1137000
Quarters > 0 > balance Sheet > short Term Investments
-
Quarters > 0 > balance Sheet > receivables
-
Quarters > 0 > balance Sheet > inventories
-
Quarters > 0 > balance Sheet > total Current Assets
3301000
Quarters > 0 > balance Sheet > property Plant Equipment
5223000
Quarters > 0 > balance Sheet > total Assets
8545000
Quarters > 0 > balance Sheet > payables
2676000
Quarters > 0 > balance Sheet > short Term Debt
-
Quarters > 0 > balance Sheet > long Term Debt
-
Quarters > 0 > balance Sheet > total Liabilities
21132000
Quarters > 0 > balance Sheet > equity
-12587000
Quarters > 0 > balance Sheet > currency_symbol
USD
Quarters > 0 > cash Flow > net Income
-6491000
Quarters > 0 > cash Flow > depreciation
568000
Quarters > 0 > cash Flow > change In Working Capital
-1859000
Quarters > 0 > cash Flow > cash From Operations
-3648000
Quarters > 0 > cash Flow > capital Expenditures
28000
Quarters > 0 > cash Flow > cash From Investing
-
Quarters > 0 > cash Flow > cash From Financing
2415000
Quarters > 0 > cash Flow > net Change In Cash
-1261000
Quarters > 0 > cash Flow > currency_symbol
USD
Quarters > 0 > ratios > PE
-4.233430206773488
Quarters > 0 > ratios > PB
-0.00001218139350123143
Quarters > 0 > ratios > ROE
51.56907920870739
Quarters > 0 > ratios > ROA
-75.96255119953189
Quarters > 0 > ratios > FCF
-3676000
Quarters > 0 > ratios > Piotroski FScore
1
Quarters > 0 > ratios > fcf Percent
-
Quarters > 0 > health Score
39
Quarters > 1 > quarter
2024-09-30
Quarters > 1 > income Statement > revenue
0
Quarters > 1 > income Statement > cost Of Revenue
-
Quarters > 1 > income Statement > gross Profit
-
Quarters > 1 > income Statement > operating Expenses
6603000
Quarters > 1 > income Statement > operating Income
-6603000
Quarters > 1 > income Statement > interest Expense
935000
Quarters > 1 > income Statement > pretax Income
-7435000
Quarters > 1 > income Statement > net Income
-7435000
Quarters > 1 > income Statement > eps
-4.809433864624301
Quarters > 1 > income Statement > dividends Per Share
-
Quarters > 1 > income Statement > shares Outstanding
1545920
Quarters > 1 > income Statement > income Tax Expense
-
Quarters > 1 > income Statement > EBITDA
-
Quarters > 1 > income Statement > operating Margin
-
Quarters > 1 > income Statement > total Other Income Expense Net
103000
Quarters > 1 > income Statement > currency_symbol
USD
Quarters > 1 > balance Sheet > cash
2924000
Quarters > 1 > balance Sheet > short Term Investments
-
Quarters > 1 > balance Sheet > receivables
-
Quarters > 1 > balance Sheet > inventories
-
Quarters > 1 > balance Sheet > total Current Assets
4303000
Quarters > 1 > balance Sheet > property Plant Equipment
5921000
Quarters > 1 > balance Sheet > total Assets
10245000
Quarters > 1 > balance Sheet > payables
1693000
Quarters > 1 > balance Sheet > short Term Debt
-
Quarters > 1 > balance Sheet > long Term Debt
-
Quarters > 1 > balance Sheet > total Liabilities
19533000
Quarters > 1 > balance Sheet > equity
-9288000
Quarters > 1 > balance Sheet > currency_symbol
USD
Quarters > 1 > cash Flow > net Income
-7435000
Quarters > 1 > cash Flow > depreciation
552000
Quarters > 1 > cash Flow > change In Working Capital
4473000
Quarters > 1 > cash Flow > cash From Operations
-1931000
Quarters > 1 > cash Flow > capital Expenditures
219000
Quarters > 1 > cash Flow > cash From Investing
-
Quarters > 1 > cash Flow > cash From Financing
1027000
Quarters > 1 > cash Flow > net Change In Cash
-1123000
Quarters > 1 > cash Flow > currency_symbol
USD
Quarters > 1 > ratios > PE
-4.809433864624301
Quarters > 1 > ratios > PB
-0.0000166442721791559
Quarters > 1 > ratios > ROE
80.04952627045651
Quarters > 1 > ratios > ROA
-72.57198633479747
Quarters > 1 > ratios > FCF
-2150000
Quarters > 1 > ratios > Piotroski FScore
1
Quarters > 1 > ratios > fcf Percent
-
Quarters > 1 > health Score
39
Quarters > 2 > quarter
2024-06-30
Quarters > 2 > income Statement > revenue
0
Quarters > 2 > income Statement > cost Of Revenue
-
Quarters > 2 > income Statement > gross Profit
-
Quarters > 2 > income Statement > operating Expenses
6353000
Quarters > 2 > income Statement > operating Income
-6353000
Quarters > 2 > income Statement > interest Expense
957000
Quarters > 2 > income Statement > pretax Income
-6825000
Quarters > 2 > income Statement > net Income
-6825000
Quarters > 2 > income Statement > eps
-4.424864822810908
Quarters > 2 > income Statement > dividends Per Share
-
Quarters > 2 > income Statement > shares Outstanding
1542420
Quarters > 2 > income Statement > income Tax Expense
-
Quarters > 2 > income Statement > EBITDA
-
Quarters > 2 > income Statement > operating Margin
-
Quarters > 2 > income Statement > total Other Income Expense Net
485000
Quarters > 2 > income Statement > currency_symbol
USD
Quarters > 2 > balance Sheet > cash
4048000
Quarters > 2 > balance Sheet > short Term Investments
-
Quarters > 2 > balance Sheet > receivables
-
Quarters > 2 > balance Sheet > inventories
-
Quarters > 2 > balance Sheet > total Current Assets
6027000
Quarters > 2 > balance Sheet > property Plant Equipment
6416000
Quarters > 2 > balance Sheet > total Assets
12464000
Quarters > 2 > balance Sheet > payables
1996000
Quarters > 2 > balance Sheet > short Term Debt
-
Quarters > 2 > balance Sheet > long Term Debt
-
Quarters > 2 > balance Sheet > total Liabilities
17634000
Quarters > 2 > balance Sheet > equity
-5170000
Quarters > 2 > balance Sheet > currency_symbol
USD
Quarters > 2 > cash Flow > net Income
-6825000
Quarters > 2 > cash Flow > depreciation
557000
Quarters > 2 > cash Flow > change In Working Capital
-2097000
Quarters > 2 > cash Flow > cash From Operations
-8180000
Quarters > 2 > cash Flow > capital Expenditures
98000
Quarters > 2 > cash Flow > cash From Investing
-
Quarters > 2 > cash Flow > cash From Financing
8781000
Quarters > 2 > cash Flow > net Change In Cash
503000
Quarters > 2 > cash Flow > currency_symbol
USD
Quarters > 2 > ratios > PE
-4.424864822810908
Quarters > 2 > ratios > PB
-0.00002983404255319149
Quarters > 2 > ratios > ROE
132.01160541586074
Quarters > 2 > ratios > ROA
-54.75770218228499
Quarters > 2 > ratios > FCF
-8278000
Quarters > 2 > ratios > Piotroski FScore
0
Quarters > 2 > ratios > fcf Percent
-
Quarters > 2 > health Score
38
Quarters > 3 > quarter
2024-03-31
Quarters > 3 > income Statement > revenue
0
Quarters > 3 > income Statement > cost Of Revenue
-
Quarters > 3 > income Statement > gross Profit
-
Quarters > 3 > income Statement > operating Expenses
5113000
Quarters > 3 > income Statement > operating Income
-5113000
Quarters > 3 > income Statement > interest Expense
1071000
Quarters > 3 > income Statement > pretax Income
-6148000
Quarters > 3 > income Statement > net Income
-6148000
Quarters > 3 > income Statement > eps
-4.772421180918077
Quarters > 3 > income Statement > dividends Per Share
-
Quarters > 3 > income Statement > shares Outstanding
1288235
Quarters > 3 > income Statement > income Tax Expense
-
Quarters > 3 > income Statement > EBITDA
-
Quarters > 3 > income Statement > operating Margin
-
Quarters > 3 > income Statement > total Other Income Expense Net
36000
Quarters > 3 > income Statement > currency_symbol
USD
Quarters > 3 > balance Sheet > cash
3676000
Quarters > 3 > balance Sheet > short Term Investments
-
Quarters > 3 > balance Sheet > receivables
-
Quarters > 3 > balance Sheet > inventories
-
Quarters > 3 > balance Sheet > total Current Assets
5568000
Quarters > 3 > balance Sheet > property Plant Equipment
7039000
Quarters > 3 > balance Sheet > total Assets
12628000
Quarters > 3 > balance Sheet > payables
2000000
Quarters > 3 > balance Sheet > short Term Debt
-
Quarters > 3 > balance Sheet > long Term Debt
-
Quarters > 3 > balance Sheet > total Liabilities
19840000
Quarters > 3 > balance Sheet > equity
-7212000
Quarters > 3 > balance Sheet > currency_symbol
USD
Quarters > 3 > cash Flow > net Income
-6148000
Quarters > 3 > cash Flow > depreciation
557000
Quarters > 3 > cash Flow > change In Working Capital
-319000
Quarters > 3 > cash Flow > cash From Operations
-5699000
Quarters > 3 > cash Flow > capital Expenditures
21000
Quarters > 3 > cash Flow > cash From Investing
-
Quarters > 3 > cash Flow > cash From Financing
6192000
Quarters > 3 > cash Flow > net Change In Cash
472000
Quarters > 3 > cash Flow > currency_symbol
USD
Quarters > 3 > ratios > PE
-4.772421180918077
Quarters > 3 > ratios > PB
-0.00001786238214087632
Quarters > 3 > ratios > ROE
85.24681087077094
Quarters > 3 > ratios > ROA
-48.68546088058283
Quarters > 3 > ratios > FCF
-5720000
Quarters > 3 > ratios > Piotroski FScore
1
Quarters > 3 > ratios > fcf Percent
-
Quarters > 3 > health Score
39
Annuals > 0 > quarter
2024-12-31
Annuals > 0 > income Statement > revenue
0
Annuals > 0 > income Statement > cost Of Revenue
8067000
Annuals > 0 > income Statement > gross Profit
-8067000
Annuals > 0 > income Statement > operating Expenses
23774000
Annuals > 0 > income Statement > operating Income
-23774000
Annuals > 0 > income Statement > interest Expense
3723000
Annuals > 0 > income Statement > pretax Income
-26898000
Annuals > 0 > income Statement > net Income
-26898000
Annuals > 0 > income Statement > eps
-17.5428756280686
Annuals > 0 > income Statement > dividends Per Share
-
Annuals > 0 > income Statement > shares Outstanding
1533272
Annuals > 0 > income Statement > income Tax Expense
-
Annuals > 0 > income Statement > EBITDA
-
Annuals > 0 > income Statement > operating Margin
-
Annuals > 0 > income Statement > total Other Income Expense Net
599000
Annuals > 0 > income Statement > currency_symbol
USD
Annuals > 0 > balance Sheet > cash
1137000
Annuals > 0 > balance Sheet > short Term Investments
-
Annuals > 0 > balance Sheet > receivables
-
Annuals > 0 > balance Sheet > inventories
-
Annuals > 0 > balance Sheet > total Current Assets
3301000
Annuals > 0 > balance Sheet > property Plant Equipment
5223000
Annuals > 0 > balance Sheet > total Assets
8545000
Annuals > 0 > balance Sheet > payables
2676000
Annuals > 0 > balance Sheet > short Term Debt
-
Annuals > 0 > balance Sheet > long Term Debt
-
Annuals > 0 > balance Sheet > total Liabilities
21132000
Annuals > 0 > balance Sheet > equity
-12587000
Annuals > 0 > balance Sheet > currency_symbol
USD
Annuals > 0 > cash Flow > net Income
-26898000
Annuals > 0 > cash Flow > depreciation
2234000
Annuals > 0 > cash Flow > change In Working Capital
198000
Annuals > 0 > cash Flow > cash From Operations
-19458000
Annuals > 0 > cash Flow > capital Expenditures
366000
Annuals > 0 > cash Flow > cash From Investing
-
Annuals > 0 > cash Flow > cash From Financing
18415000
Annuals > 0 > cash Flow > net Change In Cash
-1409000
Annuals > 0 > cash Flow > currency_symbol
USD
Annuals > 0 > ratios > PE
-17.5428756280686
Annuals > 0 > ratios > PB
-0.00001218139350123143
Annuals > 0 > ratios > ROE
213.6966711686661
Annuals > 0 > ratios > ROA
-314.7805734347572
Annuals > 0 > ratios > FCF
-19824000
Annuals > 0 > ratios > Piotroski FScore
0
Annuals > 0 > ratios > fcf Percent
-
Annuals > 0 > health Score
30
Annuals > 1 > quarter
2023-12-31
Annuals > 1 > income Statement > revenue
0
Annuals > 1 > income Statement > cost Of Revenue
2677000
Annuals > 1 > income Statement > gross Profit
-2677000
Annuals > 1 > income Statement > operating Expenses
19939000
Annuals > 1 > income Statement > operating Income
-19939000
Annuals > 1 > income Statement > interest Expense
1852000
Annuals > 1 > income Statement > pretax Income
-20949000
Annuals > 1 > income Statement > net Income
-20949000
Annuals > 1 > income Statement > eps
-16.64653624270934
Annuals > 1 > income Statement > dividends Per Share
-
Annuals > 1 > income Statement > shares Outstanding
1258460
Annuals > 1 > income Statement > income Tax Expense
-
Annuals > 1 > income Statement > EBITDA
-
Annuals > 1 > income Statement > operating Margin
-
Annuals > 1 > income Statement > total Other Income Expense Net
842000
Annuals > 1 > income Statement > currency_symbol
USD
Annuals > 1 > balance Sheet > cash
3204000
Annuals > 1 > balance Sheet > short Term Investments
-
Annuals > 1 > balance Sheet > receivables
-
Annuals > 1 > balance Sheet > inventories
-
Annuals > 1 > balance Sheet > total Current Assets
4430000
Annuals > 1 > balance Sheet > property Plant Equipment
7718000
Annuals > 1 > balance Sheet > total Assets
12169000
Annuals > 1 > balance Sheet > payables
2136000
Annuals > 1 > balance Sheet > short Term Debt
-
Annuals > 1 > balance Sheet > long Term Debt
-
Annuals > 1 > balance Sheet > total Liabilities
21290000
Annuals > 1 > balance Sheet > equity
-9121000
Annuals > 1 > balance Sheet > currency_symbol
USD
Annuals > 1 > cash Flow > net Income
-20949000
Annuals > 1 > cash Flow > depreciation
2221000
Annuals > 1 > cash Flow > change In Working Capital
-5009000
Annuals > 1 > cash Flow > cash From Operations
-21225000
Annuals > 1 > cash Flow > capital Expenditures
207000
Annuals > 1 > cash Flow > cash From Investing
-
Annuals > 1 > cash Flow > cash From Financing
23991000
Annuals > 1 > cash Flow > net Change In Cash
2559000
Annuals > 1 > cash Flow > currency_symbol
USD
Annuals > 1 > ratios > PE
-16.64653624270934
Annuals > 1 > ratios > PB
-0.000013797390636991559
Annuals > 1 > ratios > ROE
229.6787632934985
Annuals > 1 > ratios > ROA
-172.1505464705399
Annuals > 1 > ratios > FCF
-21432000
Annuals > 1 > ratios > Piotroski FScore
1
Annuals > 1 > ratios > fcf Percent
-
Annuals > 1 > health Score
31
Annuals > 2 > quarter
2022-12-31
Annuals > 2 > income Statement > revenue
0
Annuals > 2 > income Statement > cost Of Revenue
-
Annuals > 2 > income Statement > gross Profit
-
Annuals > 2 > income Statement > operating Expenses
31114300
Annuals > 2 > income Statement > operating Income
-31114300
Annuals > 2 > income Statement > interest Expense
166500
Annuals > 2 > income Statement > pretax Income
-34731000
Annuals > 2 > income Statement > net Income
-34731000
Annuals > 2 > income Statement > eps
-53.56556232967243
Annuals > 2 > income Statement > dividends Per Share
-
Annuals > 2 > income Statement > shares Outstanding
648383
Annuals > 2 > income Statement > income Tax Expense
-
Annuals > 2 > income Statement > EBITDA
-
Annuals > 2 > income Statement > operating Margin
-
Annuals > 2 > income Statement > total Other Income Expense Net
-3450200
Annuals > 2 > income Statement > currency_symbol
USD
Annuals > 2 > balance Sheet > cash
645200
Annuals > 2 > balance Sheet > short Term Investments
-
Annuals > 2 > balance Sheet > receivables
0
Annuals > 2 > balance Sheet > inventories
-
Annuals > 2 > balance Sheet > total Current Assets
1688900
Annuals > 2 > balance Sheet > property Plant Equipment
10254200
Annuals > 2 > balance Sheet > total Assets
11967500
Annuals > 2 > balance Sheet > payables
7308100
Annuals > 2 > balance Sheet > short Term Debt
-
Annuals > 2 > balance Sheet > long Term Debt
2914000
Annuals > 2 > balance Sheet > total Liabilities
17742200
Annuals > 2 > balance Sheet > equity
-5774700
Annuals > 2 > balance Sheet > currency_symbol
USD
Annuals > 2 > cash Flow > net Income
-34731000
Annuals > 2 > cash Flow > depreciation
1673400
Annuals > 2 > cash Flow > change In Working Capital
4369900
Annuals > 2 > cash Flow > cash From Operations
-23745900
Annuals > 2 > cash Flow > capital Expenditures
4880500
Annuals > 2 > cash Flow > cash From Investing
-
Annuals > 2 > cash Flow > cash From Financing
3902700
Annuals > 2 > cash Flow > net Change In Cash
-24708700
Annuals > 2 > cash Flow > currency_symbol
USD
Annuals > 2 > ratios > PE
-53.56556232967243
Annuals > 2 > ratios > PB
-0.000011227994527854262
Annuals > 2 > ratios > ROE
601.4338407189983
Annuals > 2 > ratios > ROA
-290.2109880927512
Annuals > 2 > ratios > FCF
-28626400
Annuals > 2 > ratios > Piotroski FScore
0
Annuals > 2 > ratios > fcf Percent
-
Annuals > 2 > health Score
30
Annuals > 3 > quarter
2021-12-31
Annuals > 3 > income Statement > revenue
0
Annuals > 3 > income Statement > cost Of Revenue
-
Annuals > 3 > income Statement > gross Profit
-
Annuals > 3 > income Statement > operating Expenses
25305700
Annuals > 3 > income Statement > operating Income
-25305700
Annuals > 3 > income Statement > interest Expense
12200
Annuals > 3 > income Statement > pretax Income
-25588700
Annuals > 3 > income Statement > net Income
-25588700
Annuals > 3 > income Statement > eps
-49.563320891836455
Annuals > 3 > income Statement > dividends Per Share
-
Annuals > 3 > income Statement > shares Outstanding
516283
Annuals > 3 > income Statement > income Tax Expense
-
Annuals > 3 > income Statement > EBITDA
-
Annuals > 3 > income Statement > operating Margin
-
Annuals > 3 > income Statement > total Other Income Expense Net
-270800
Annuals > 3 > income Statement > currency_symbol
USD
Annuals > 3 > balance Sheet > cash
25353900
Annuals > 3 > balance Sheet > short Term Investments
-
Annuals > 3 > balance Sheet > receivables
16200
Annuals > 3 > balance Sheet > inventories
-
Annuals > 3 > balance Sheet > total Current Assets
27069500
Annuals > 3 > balance Sheet > property Plant Equipment
3629000
Annuals > 3 > balance Sheet > total Assets
30729600
Annuals > 3 > balance Sheet > payables
2214300
Annuals > 3 > balance Sheet > short Term Debt
-
Annuals > 3 > balance Sheet > long Term Debt
-
Annuals > 3 > balance Sheet > total Liabilities
3409800
Annuals > 3 > balance Sheet > equity
27319800
Annuals > 3 > balance Sheet > currency_symbol
USD
Annuals > 3 > cash Flow > net Income
-25588700
Annuals > 3 > cash Flow > depreciation
469800
Annuals > 3 > cash Flow > change In Working Capital
710300
Annuals > 3 > cash Flow > cash From Operations
-20321500
Annuals > 3 > cash Flow > capital Expenditures
1894800
Annuals > 3 > cash Flow > cash From Investing
-
Annuals > 3 > cash Flow > cash From Financing
37335700
Annuals > 3 > cash Flow > net Change In Cash
15203400
Annuals > 3 > cash Flow > currency_symbol
USD
Annuals > 3 > ratios > PE
-49.563320891836455
Annuals > 3 > ratios > PB
0.0000018897759134400693
Annuals > 3 > ratios > ROE
-93.66357001149349
Annuals > 3 > ratios > ROA
-83.27052743934186
Annuals > 3 > ratios > FCF
-22216300
Annuals > 3 > ratios > Piotroski FScore
0
Annuals > 3 > ratios > fcf Percent
-
Annuals > 3 > health Score
33
Valuation > metrics > PE
-4.233430206773488
Valuation > metrics > PB
-0.00001218139350123143
Valuation > final Score
50
Valuation > verdict
Fair
Profitability > metrics > ROE
51.56907920870739
Profitability > metrics > ROA
-196.6373826113299
Profitability > final Score
55
Profitability > verdict
Weak
Risk > metrics > Interest Coverage
-7.447780678851175
Risk > final Score
0
Risk > verdict
High
Liquidity > metrics > Current Ratio
1.2335575485799701
Liquidity > metrics > Quick Ratio
1.2335575485799701
Liquidity > final Score
81
Liquidity > verdict
Great
Prev Valuations > 0
50
Prev Valuations > 1
50
Prev Valuations > 2
50
Prev Profitabilities > 0
55
Prev Profitabilities > 1
55
Prev Profitabilities > 2
55
Prev Risks > 0
2
Prev Risks > 1
3
Prev Risks > 2
11
Prev Liquidities > 0
100
Prev Liquidities > 1
100
Prev Liquidities > 2
100
Updated At
2026-01-20T22:06:35.400Z
Earnings History > 0 > period
2024-12-31
Earnings History > 0 > report Date
2025-02-14
Earnings History > 0 > date
2024-12-31
Earnings History > 0 > before After Market
-
Earnings History > 0 > currency
-
Earnings History > 0 > eps Actual
13.13
Earnings History > 0 > eps Estimate
-
Earnings History > 0 > eps Difference
0
Earnings History > 0 > surprise Percent
-
Earnings History > 1 > period
2024-09-30
Earnings History > 1 > report Date
2024-11-29
Earnings History > 1 > date
2024-09-30
Earnings History > 1 > before After Market
-
Earnings History > 1 > currency
-
Earnings History > 1 > eps Actual
-6.1174
Earnings History > 1 > eps Estimate
-
Earnings History > 1 > eps Difference
0
Earnings History > 1 > surprise Percent
-
Earnings History > 2 > period
2024-06-30
Earnings History > 2 > report Date
2024-08-09
Earnings History > 2 > date
2024-06-30
Earnings History > 2 > before After Market
-
Earnings History > 2 > currency
-
Earnings History > 2 > eps Actual
-5.5396
Earnings History > 2 > eps Estimate
-
Earnings History > 2 > eps Difference
0
Earnings History > 2 > surprise Percent
-
Earnings History > 3 > period
2024-03-31
Earnings History > 3 > report Date
2024-05-10
Earnings History > 3 > date
2024-03-31
Earnings History > 3 > before After Market
-
Earnings History > 3 > currency
-
Earnings History > 3 > eps Actual
-5.4601
Earnings History > 3 > eps Estimate
-
Earnings History > 3 > eps Difference
0
Earnings History > 3 > surprise Percent
-
Earnings History > 4 > period
2023-12-31
Earnings History > 4 > report Date
2024-02-28
Earnings History > 4 > date
2023-12-31
Earnings History > 4 > before After Market
-
Earnings History > 4 > currency
-
Earnings History > 4 > eps Actual
-4.4977
Earnings History > 4 > eps Estimate
-
Earnings History > 4 > eps Difference
0
Earnings History > 4 > surprise Percent
-
Earnings History > 5 > period
2023-09-30
Earnings History > 5 > report Date
2023-11-13
Earnings History > 5 > date
2023-09-30
Earnings History > 5 > before After Market
-
Earnings History > 5 > currency
-
Earnings History > 5 > eps Actual
-4.2762
Earnings History > 5 > eps Estimate
-
Earnings History > 5 > eps Difference
0
Earnings History > 5 > surprise Percent
-
Earnings History > 6 > period
2023-06-30
Earnings History > 6 > report Date
2023-08-11
Earnings History > 6 > date
2023-06-30
Earnings History > 6 > before After Market
-
Earnings History > 6 > currency
-
Earnings History > 6 > eps Actual
-6.9862
Earnings History > 6 > eps Estimate
-
Earnings History > 6 > eps Difference
0
Earnings History > 6 > surprise Percent
-
Earnings History > 7 > period
2023-03-31
Earnings History > 7 > report Date
2023-05-12
Earnings History > 7 > date
2023-03-31
Earnings History > 7 > before After Market
-
Earnings History > 7 > currency
-
Earnings History > 7 > eps Actual
-6.17
Earnings History > 7 > eps Estimate
-0.29
Earnings History > 7 > eps Difference
-5.88
Earnings History > 7 > surprise Percent
-2027.5862
Earnings History > 8 > period
2022-12-31
Earnings History > 8 > report Date
2023-03-29
Earnings History > 8 > date
2022-12-31
Earnings History > 8 > before After Market
-
Earnings History > 8 > currency
-
Earnings History > 8 > eps Actual
0
Earnings History > 8 > eps Estimate
-0.56
Earnings History > 8 > eps Difference
0.56
Earnings History > 8 > surprise Percent
100
Earnings History > 9 > period
2022-09-30
Earnings History > 9 > report Date
2022-11-23
Earnings History > 9 > date
2022-09-30
Earnings History > 9 > before After Market
-
Earnings History > 9 > currency
-
Earnings History > 9 > eps Actual
-0.75
Earnings History > 9 > eps Estimate
-0.56
Earnings History > 9 > eps Difference
-0.19
Earnings History > 9 > surprise Percent
-33.9286
Earnings History > 10 > period
2022-06-30
Earnings History > 10 > report Date
2022-08-12
Earnings History > 10 > date
2022-06-30
Earnings History > 10 > before After Market
-
Earnings History > 10 > currency
-
Earnings History > 10 > eps Actual
-0.54
Earnings History > 10 > eps Estimate
-0.41
Earnings History > 10 > eps Difference
-0.13
Earnings History > 10 > surprise Percent
-31.7073
Earnings History > 11 > period
2022-03-31
Earnings History > 11 > report Date
2022-04-08
Earnings History > 11 > date
2022-03-31
Earnings History > 11 > before After Market
-
Earnings History > 11 > currency
-
Earnings History > 11 > eps Actual
-0.69
Earnings History > 11 > eps Estimate
-0.27
Earnings History > 11 > eps Difference
-0.42
Earnings History > 11 > surprise Percent
-155.5556
Earnings History > 12 > period
2021-12-31
Earnings History > 12 > report Date
2022-03-11
Earnings History > 12 > date
2021-12-31
Earnings History > 12 > before After Market
-
Earnings History > 12 > currency
-
Earnings History > 12 > eps Actual
-0.4
Earnings History > 12 > eps Estimate
-0.26
Earnings History > 12 > eps Difference
-0.14
Earnings History > 12 > surprise Percent
-53.8462
Earnings History > 13 > period
2021-06-30
Earnings History > 13 > report Date
2021-08-13
Earnings History > 13 > date
2021-06-30
Earnings History > 13 > before After Market
-
Earnings History > 13 > currency
-
Earnings History > 13 > eps Actual
-0.68
Earnings History > 13 > eps Estimate
-
Earnings History > 13 > eps Difference
0
Earnings History > 13 > surprise Percent
-
Earnings History > 14 > period
2021-03-31
Earnings History > 14 > report Date
2021-05-14
Earnings History > 14 > date
2021-03-31
Earnings History > 14 > before After Market
-
Earnings History > 14 > currency
-
Earnings History > 14 > eps Actual
-0.53
Earnings History > 14 > eps Estimate
-
Earnings History > 14 > eps Difference
0
Earnings History > 14 > surprise Percent
-
Earnings History > 15 > period
2020-12-31
Earnings History > 15 > report Date
2021-03-31
Earnings History > 15 > date
2020-12-31
Earnings History > 15 > before After Market
-
Earnings History > 15 > currency
-
Earnings History > 15 > eps Actual
-0.49
Earnings History > 15 > eps Estimate
-
Earnings History > 15 > eps Difference
0
Earnings History > 15 > surprise Percent
-
Earnings History > 16 > period
2020-09-30
Earnings History > 16 > report Date
2020-11-30
Earnings History > 16 > date
2020-09-30
Earnings History > 16 > before After Market
-
Earnings History > 16 > currency
-
Earnings History > 16 > eps Actual
-0.33
Earnings History > 16 > eps Estimate
0
Earnings History > 16 > eps Difference
-0.33
Earnings History > 16 > surprise Percent
-
Kiromic BioPharma, Inc., a clinical stage biotherapeutics company, engages in the utilization of non-engineered an engineered allogeneic Gamma Delta T (GDT) cell technologies to develop therapies for solid tumors in the United States. The company's lead product candidate is the Deltacel-01, which is in Phase 1 clinical trial, in combination with low-dose targeted radiation for patients with non-small cell lung cancer. It also develops Isocel, which is clinical trial in combination with low-dose radiation to treat Mesothelin Isoform 2 positive solid malignancies; Procel, which is in clinical trial in combination with low-dose radiation to treat PD-L1 positive solid malignancies; ALEXIS-ISO-1, which is in clinical trial to evaluate Isocel in patients with Mesothelin Isoform 2 positive solid malignancies; and ALEXIS-PRO-1, which is in clinical trial to evaluate Procel in patients with PD-L1 positive solid malignancies. It has a license agreement with Longwood University. The company was formerly known as Kiromic, Inc. and changed its name to Kiromic BioPharma, Inc. in December 2019. Kiromic BioPharma, Inc. was founded in 2006 and is headquartered in Houston, Texas. On March 21, 2025, Kiromic BioPharma, Inc. filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the District of Delaware.
Stock Price
$0.00
decrease compared to yesterday.
Dividend
Frequency:
Rate:
N/ANext Payout:
N/A(Last Updated 2024-12-31)
Health Score
Price to Book Ratio (P/B)
-
Very Low
Low ≤ 1
High ≥ 3
Return on Equity (ROE)
-
Very High
Low ≤ 5%
High ≥ 25%
Return on Assets (ROA)
-
Very Low
Low ≤ 2%
High ≥ 10%
* Institutions hold a combined 0.00% of the total shares of Kiromic BioPharma, Inc.
* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.
Date
—
EPS Estimate
—
Date
2024-12-31
EPS Actual
13.13
EPS Estimate
—
EPS Difference
0
Surprise Percent
0%
(Last Updated 2024-12-31)
(Last Updated 2024-12-31)
Revenue
$ 0
Cost Of Revenue
$ 0
Gross Profit
$ 0
Operating Expenses
$ 0
Operating Income
$ 0
Interest Expense
$ 0
Pretax Income
$ 0
Net Income
$ 0
Income Tax Expense
$ 0
EBITDA
$ 0
Total Other Income Expense Net
$ 0
Earnings Per Share
0
Dividends Per Share
0
Shares Outstanding
0
Operating Margin
0%
(Last Updated 2024-12-31)
Cash
$ 0
Short Term Investments
$ 0
Receivables
$ 0
Inventories
$ 0
Total Current Assets
$ 0
Property Plant Equipment
$ 0
Total Assets
$ 0
Payables
$ 0
Short Term Debt
$ 0
Long Term Debt
$ 0
Total Liabilities
$ 0
Equity
$ 0
(Last Updated 2024-12-31)
Net Income
$ 0
Depreciation
$ 0
Change In Working Capital
$ 0
Cash From Operations
$ 0
Capital Expenditures
$ 0
Cash From Investing
$ 0
Cash From Financing
$ 0
Net Change In Cash
$ 0
Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.